Lexaria Bioscience (LEXX) has begun dosing in the Company’s Phase 1b, 12-week chronic study GLP-1-H24-4. The Study is designed mainly to determine whether Lexaria’s proprietary DehydraTECH technology improves the safety and effectiveness of existing GLP-1 drugs. The Study arms are as follows: Arm 1 – DehydraTECH-CBD capsules; Arm 2 – DehydraTECH-semaglutide capsules; Arm 3 – DehydraTECH-semaglutide combined with DehydraTECH-CBD capsules; Arm 4 – Rybelsus tablets; Arm 5 – DehydraTECH-tirzepatide capsules. Quality control release testing of the clinical test articles has now been completed. The Study is planned to be conducted using seven clinical investigational sites in Australia as a registrational Phase 1b study within Australian clinical regulatory authority regulations. The Study, upon completion, is expected to be regarded as the equivalent of a Phase 1b registrational study by the U.S. Food and Drug Administration
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on LEXX:
- Lexaria Bioscience Bolsters Drug Delivery Strategy
- Lexaria Bioscience forms Scientific Advisory Board
- Lexaria Bioscience Welcomes New Chief Medical Advisor
- Lexaria Bioscience appoints Michael Gibson as chief medical advisor
- Lexaria Bioscience Explores Oral Liraglutide Potential
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
